American Century Companies Inc. Has $13.08 Million Stock Position in Mineralys Therapeutics, Inc. $MLYS

American Century Companies Inc. lowered its stake in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) by 2.9% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 823,616 shares of the company’s stock after selling 25,014 shares during the period. American Century Companies Inc. owned approximately 1.27% of Mineralys Therapeutics worth $13,079,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. SBI Securities Co. Ltd. raised its holdings in shares of Mineralys Therapeutics by 297.5% during the first quarter. SBI Securities Co. Ltd. now owns 1,590 shares of the company’s stock valued at $25,000 after purchasing an additional 1,190 shares during the period. BNP Paribas Financial Markets acquired a new position in shares of Mineralys Therapeutics during the fourth quarter valued at about $48,000. CWM LLC raised its holdings in shares of Mineralys Therapeutics by 59.3% during the first quarter. CWM LLC now owns 8,342 shares of the company’s stock valued at $132,000 after purchasing an additional 3,105 shares during the period. GAMMA Investing LLC raised its holdings in shares of Mineralys Therapeutics by 9,602.2% in the 1st quarter. GAMMA Investing LLC now owns 8,829 shares of the company’s stock worth $140,000 after acquiring an additional 8,738 shares during the last quarter. Finally, ProShare Advisors LLC acquired a new stake in shares of Mineralys Therapeutics in the 4th quarter worth about $128,000. Institutional investors and hedge funds own 84.46% of the company’s stock.

Insiders Place Their Bets

In other Mineralys Therapeutics news, CFO Adam Scott Levy sold 59,925 shares of the company’s stock in a transaction dated Wednesday, July 30th. The shares were sold at an average price of $14.76, for a total value of $884,493.00. Following the completion of the sale, the chief financial officer directly owned 132,934 shares of the company’s stock, valued at approximately $1,962,105.84. This represents a 31.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider David Malcom Rodman sold 11,365 shares of the stock in a transaction that occurred on Wednesday, August 13th. The shares were sold at an average price of $12.93, for a total transaction of $146,949.45. Following the transaction, the insider directly owned 92,891 shares of the company’s stock, valued at $1,201,080.63. This represents a 10.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 123,051 shares of company stock valued at $1,776,262. Corporate insiders own 33.24% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on MLYS shares. Guggenheim set a $48.00 target price on shares of Mineralys Therapeutics and gave the stock a “buy” rating in a report on Wednesday, May 14th. Wall Street Zen upgraded shares of Mineralys Therapeutics from a “sell” rating to a “hold” rating in a report on Friday. Jefferies Financial Group started coverage on shares of Mineralys Therapeutics in a report on Tuesday, June 10th. They issued a “hold” rating and a $15.00 target price on the stock. Finally, HC Wainwright restated a “buy” rating and issued a $42.00 target price on shares of Mineralys Therapeutics in a report on Wednesday, August 13th. Three research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $32.25.

Mineralys Therapeutics Stock Performance

Shares of MLYS stock opened at $14.74 on Tuesday. Mineralys Therapeutics, Inc. has a 52-week low of $8.24 and a 52-week high of $18.38. The company has a 50-day simple moving average of $14.03 and a two-hundred day simple moving average of $13.77. The company has a market capitalization of $977.11 million, a price-to-earnings ratio of -4.14 and a beta of -0.29.

Mineralys Therapeutics (NASDAQ:MLYS) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.66) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.12. On average, sell-side analysts forecast that Mineralys Therapeutics, Inc. will post -4.23 EPS for the current fiscal year.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.